Form 4: Insider Transfer of Ocular Therapeutix Shares

Pravin Dugel, Director and Officer of Ocular Therapeutix, Inc., transferred 394,696 shares to his spouse on April 9, 2026.

Summary

• Pravin Dugel, who holds the positions of Director and Officer at Ocular Therapeutix, Inc., executed a transaction on April 9, 2026.
• The transaction involved the transfer of 394,696 shares of common stock.
• These shares were transferred to his spouse without any consideration.
• Following this transfer, Mr. Dugel directly owns 2,618,326 shares of common stock.
• Additionally, he has indirect beneficial ownership of 394,696 shares through his spouse and 300,115 shares through the 2024 Irrevocable Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a routine transfer of shares between related parties without immediate implications for the company's financial performance or strategic direction.

Positives

• The reporting person, Pravin Dugel, continues to hold a significant number of shares directly (2,618,326) and indirectly, indicating continued investment in the company.
• The transfer was made to a spouse, which may not represent a divestment from the family's overall beneficial ownership.

Negatives

• A substantial number of shares (394,696) were transferred, which could be interpreted as a reduction in direct control or beneficial ownership by the reporting person, although it remains within the family unit.
• The transfer was made for no consideration, which is a factual detail of the transaction but does not inherently indicate a positive or negative financial outcome for the reporting person at the time of transfer.

Future Outlook

This filing is a statement of changes in beneficial ownership and does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions. While this specific filing details a share transfer between related parties, it is important for investors to monitor such transactions for patterns that might indicate changes in insider confidence or strategic shifts within the biotechnology sector.

Related Party Transactions

• Transfer of 394,696 shares of common stock from Pravin Dugel to his spouse for no consideration on April 9, 2026.

Stakeholder Impact

• Shareholders: The transfer does not immediately impact the total beneficial ownership of the Dugel family, but a large transfer could be noted by investors monitoring insider activity.
• Employees: No direct impact is indicated.
• Creditors: No direct impact is indicated.
• Suppliers: No direct impact is indicated.
• Customers: No direct impact is indicated.

Key Dates

Keywords

Ocular Therapeutix, SEC Form 4, Insider Trading, Share Transfer, Beneficial Ownership, Pravin Dugel, Common Stock